MiMedx Group, Inc. (NASDAQ:MDXG) Position Trimmed by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 65.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 70,721 shares of the company’s stock after selling 134,267 shares during the period. Cubist Systematic Strategies LLC’s holdings in MiMedx Group were worth $490,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Isthmus Partners LLC increased its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of MiMedx Group during the first quarter worth about $27,000. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group during the second quarter worth about $40,000. Quest Partners LLC bought a new position in shares of MiMedx Group during the second quarter worth about $81,000. Finally, Entropy Technologies LP bought a new position in shares of MiMedx Group during the first quarter worth about $99,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $5.71 on Friday. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $9.27. The company has a current ratio of 3.85, a quick ratio of 3.22 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $838.29 million, a price-to-earnings ratio of 10.20 and a beta of 1.97. The firm has a 50-day moving average of $6.20 and a two-hundred day moving average of $6.78.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. The company had revenue of $87.21 million during the quarter, compared to the consensus estimate of $88.44 million. As a group, analysts expect that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MDXG. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. Craig Hallum reduced their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.